Novo, Pfizer and Nan Fung helped provide $93.5m for the Stanford immunotherapy spinout as it advances its lead asset towards the clinic.
Bolt Biotherapeutics, a US-based cancer therapy spinout of Stanford University, yesterday closed a $93.5m series C round backed by pharmaceutical firms Pfizer and Novo, as well as property development group Nan Fung.
Venture capital firm Sofinnova Investments led the round, which also featured RA Capital Management, Surveyor Capital, Rock Springs Capital, Samsara BioCapital, Vivo Capital and undisclosed additional investors.
Pfizer invested in the round through its corporate venture capital arm, Pfizer Ventures, while Nan Fung took part through life science investment vehicle Pivotal BioVenture Partners.
Founded in 2015, Bolt is working on immunotherapies designed to fight tumours and equip the body’s immune system with the ability to respond to cancerous cells in future.
The company’s lead asset, BDC-1001, targets HER2-expressing solid tumours, and has shown promising results in preclinical studies. HER2 is a protein that promotes the growth of cancer cells.
The series C funding…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
